
View larger version (66K):
[in a new window]
|
Fig. 3. Binding of Ii sequences to YWD DR1 mutants. (A) DR1ß chain mutants (lanes 4 to 18) and DR1ß chain (lanes 1 to 3) were co-expressed with DR and tested for binding to full-length Ii (wt Ii, lanes 1, 4, 7, 10, 13, and 16), and to the Ii91-99 mutant with the MHCII groove-binding sequence aa 91-99 replaced by an irrelevant sequence (lanes 2, 5, 8, 11, 14, and 17), or to the mutant Ii82-99 where the complete MHCII-binding sequence including the proline-rich sequence of Ii was replaced by an unrelated sequence (lanes 3, 6, 9, 12, 15 and 18). Cell lysates were immunoprecipitated (IP) with I251 against DR. The immunocomplexes and cell lysates (lysate control) were separated by SDS-PAGE, immunoblotted and detected with antibodies against Ii or the DR subunits. Heavy (H) and light (L) chains are indicated. (B) The DR3ß chain mutant (YWD to AAA) or the wild-type DR3ß chain were co-expressed with DR and full-length Ii (wt Ii, lanes 1 and 4), Ii91-99mut (lanes 2 and 5), or Ii82-99 mut (lanes 3 and 6). COS-7 cells were lysed in 0.5% NP40 and immunoprecipitated (IP) against DR (mAb I251). Subsequently, the immunoprecipitates were blotted against Ii (upper panel) and the lysates were immunoblotted with antibodies against Ii, DR , or DRß chains (lower panel).
|